Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018

As a number of drug makers jostle in a race to develop hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors as next-generation renal anemia treatments, Astellas Pharma’s roxadustat is likely to be the first-in-class among five APIs currently being developed in Japan...read more